γδ t-pd-1 ab cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2024 (NCT06404281)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07172178 | Early Phase 1 (Phase 1) | Oct 15, 2025 | Nanjing Medical University |
| NCT06404281 | Phase 1 | Aug 1, 2024 | Changzhou No.2 People's Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Changzhou No.2 People's Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1